Released : March 20, 2017 07:00 RNS Number : 8799Z MaxCyte, Inc. 20 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2016 Consistent top-line growth with 32% increase in revenues and gross margins approaching 90% Maryland,
Released : March 14, 2017 07:00 RNS Number : 3349Z MaxCyte, Inc. 14 March 2017 MaxCyte, Inc. ("MaxCyte") CRISPR THERAPEUTICS/CASEBIA OBTAIN MAXCYTE COMMERCIAL LICENSE CRISPR Therapeutics and Casebia obtain commercial rights to MaxCyte's cell engineering platform to develop
Released : March 02, 2017 07:00 RNS Number : 3008Y MaxCyte, Inc. 02 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting - In vivo research demonstrates potential of novel, proprietary, CARMA product candidate for use
Released : March 01, 2017 07:00 RNS Number : 0875Y MaxCyte, Inc. 01 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Full Year Results Maryland, USA - 1 March 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to accelerating the discovery, development,
Released : January 24, 2017 07:00 RNS Number : 9020U MaxCyte, Inc. 24 January 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Consecutive 30 percent year-on year revenue growth Maryland, USA - 24 January 2017: MaxCyte (LSE: MXCT), the developer and supplier of cell
Released : January 12, 2017 07:00 RNS Number : 9615T MaxCyte, Inc. 12 January 2017 MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 X-Linked CGD Gene Repair - MaxCyte's Proprietary GT® System fosters translational development of ex
Released : January 03, 2017 14:49 RNS Number : 2281T MaxCyte, Inc. 03 January 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Issue of Equity from exercise of Share Options Maryland, USA -03 January 2017: MaxCyte (LSE: MXCT) announces the issue and allotment of 18,293 new shares of
Released : December 21, 2016 07:00 RNS Number : 4115S MaxCyte, Inc. 21 December 2016 MaxCyte Announces Collaboration to Further Advance CARMA - Preclinical research to focus on developing therapies based on MaxCyte's proprietary CARMA platform - CARMA has potential for broad
Released : December 06, 2016 09:34 RNS Number : 0823R MaxCyte, Inc. 06 December 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Issue of Equity from exercise of Share Options Maryland, USA - 06 December 2016: MaxCyte (LSE: MXCT), announces the issue and allotment of 12,805 new
Released : October 27, 2016 07:00 RNS Number : 5694N MaxCyte, Inc. 27 October 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of Annual General Meeting Maryland, USA - 27 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based
